rem0046127
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2020 (NCT04672135)
Timeline
Indications
Studied for
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05478031 | Phase 2 | Jun 7, 2022 | reMYND, University of Amsterdam |
| NCT04672135 | Phase 1 | Nov 9, 2020 | NeuroScios GmbH, reMYND |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| reMYND | For profit | 2 | 2 | 2 | 2020 |
| NeuroScios GmbH | For profit | 1 | 0 | 1 | 2020 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1